Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00615940 · ClinicalTrials.gov registry record · Phase 2
Combination of Oral WX-671 Plus Capecitabine vs. Capecitabine Monotherapy in First-line Her2-negative Metastatic Breast Cancer
A Phase 2 study, sponsored by Heidelberg Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 132
- Enrollment target
NCT00615940: Completed Phase 2 study, sponsored by Heidelberg Pharma.
NCT00615940 is a Phase 2 study that has completed, run by Heidelberg Pharma. The registered enrollment target is 132 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00615940, a Phase 2 study, has completed, sponsored by Heidelberg Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 132 participants
- Enrollment target
Study Summary
This randomized, double-blind, placebo controlled phase II trial is studying how well capecitabine works when given in combination with WX-671 or when given alone in treating patients receiving first-line therapy for her2negative metastatic breast cancer.
Interventions
- DRUG placebo
- DRUG WX-671
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 132 participants |
| Start Date | 2008-07 |
| Est. Completion | 2012-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00615940
The ClinicalTrials.gov registry entry for NCT00615940 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 132 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Heidelberg Pharma, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00615940 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00615940 about?
NCT00615940 is a clinical study titled "Combination of Oral WX-671 Plus Capecitabine vs. Capecitabine Monotherapy in First-line Her2-negative Metastatic Breast Cancer". This randomized, double-blind, placebo controlled phase II trial is studying how well capecitabine works when given in combination with WX-671 or when given alone in treating patients receiving first-line therapy for her2negative metastatic breast cancer.
What is the current status of trial NCT00615940?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 132 participants. The study started on 2008-07. Estimated completion is 2012-04.
What interventions are being tested in trial NCT00615940?
The interventions under investigation include: placebo (DRUG), WX-671 (DRUG).
Who is sponsoring clinical trial NCT00615940?
This trial is sponsored by Heidelberg Pharma, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.